Active clinical studies are addressing important questions including combinations of dual ICIs and ICI + Vascular Endothelial Growth Factor (VEGF) inhibitors + chemotherapy in progressive EGFRm NSCLC that are of significant interest to researchers and clinicians in the field. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.